NEW YORK, Dec. 15 Reportlinker.com announces that a new market research report is available in its catalogue:
The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Advertisement
http://www.reportlinker.com/p0168107/The-Future-of-Metabolic-Disorder-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html
Advertisement
Summary
The author has released its latest research "The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
The scope of this report includes:
-- Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015
-- Analysis of the leading therapeutic segments including diabetes and obesity.
-- Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
-- Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
-- Key drivers and barriers that have a significant impact on the market
-- Coverage of pipeline molecules in various phases of drug development
-- Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
-- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
-- Align product portfolio to the markets with high growth potential
-- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
-- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
-- Develop key strategic initiatives by understanding key focus areas of leading companies
-- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
1 Table of Contents
1 Executive Summary
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 GBI Research Report Guidance
4 Global Metabolic Disorder Therapeutics Market: Market Overview
4.1 Introduction
4.2 Revenue Forecasts for the Global Metabolic Disorder Therapeutics Market
4.2.1 Sales Value
4.2.2 Sales Volume
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Usage Patterns
4.2.5 Geographical Segmentation
4.2.6 Generics' Share in the Global Metabolic Disorders Market
4.3 SWOT Analysis
4.3.1 Strength
4.3.2 Weakness
4.3.3 Opportunity
4.3.4 Threat
4.4 Metabolic Disorder Therapeutics Market Drivers
4.4.1 Steady Growth in the Ageing Population
4.4.2 Improvements in the Diagnosis of the Disease
4.4.3 Launch of New Treatments with More Innovative Medicines in Pipeline
4.4.4 Increase in the Incidence of Lifestyle Diseases such as Obesity and Diabetes
4.5 Metabolic Disorder Therapeutics Market Restraints
4.5.1 Patent Expirations
4.5.2 Concerns over Drug Safety
4.5.3 Tightened Reimbursement pressures causing problems in the global Metabolic Disorder Therapeutics market growth
5 Global Metabolic Disorder Therapeutics Market: Geographical Distribution of Revenues
5.1 Geographic Break-up
5.2 The US
5.2.1 Sales Value
5.2.2 Sales Volume
5.2.3 Annual Cost of Therapy
5.2.4 Treatment Usage Patterns
5.3 Top Five Countries in Europe
5.3.1 Sales Value
5.3.2 Sales Volume
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Usage Patterns
5.4 Japan
5.4.1 Sales Value
5.4.2 Sales Volume
5.4.3 Annual Cost of Therapy
5.4.4 Treatment Usage Patterns
6 Global Metabolic Disorder Therapeutics Market: Therapeutic Distribution of Revenues
6.1 Diabetes Market
6.1.1 Introduction
6.1.2 Unmet Needs
6.1.3 Sales Value
6.1.4 Sales Volume
6.1.5 Annual Cost of Therapy
6.1.6 Treatment Usage Patterns
6.1.7 Geographical Segmentation
6.1.8 Generics' Share in the Global Diabetes Market
6.1.9 Drivers
6.1.10 Inhibitors
6.2 Obesity Market
6.2.1 Introduction
6.2.2 Sales Value
6.2.3 Sales Volume
6.2.4 Annual Cost of Therapy
6.2.5 Treatment Usage Patterns
6.2.6 Geographical Segmentation
6.2.7 Generics' Share in the Global Obesity Market
6.2.8 Drivers of Obesity Market
6.2.9 Restraints of Obesity Market
7 Global Metabolic Disorder Therapeutics Market: Pipeline Analysis
7.1 Introduction
7.1.1 Obesity
7.1.2 R&D Strategies
7.2 R&D Trends
7.2.1 New Promising Treatments for Diabetic Retinopathy
7.2.2 Identifying Biomarkers
7.2.3 Combination Drugs
7.2.4 First-in-class Insulin Pills (oral delivery) in Development
7.3 New Drug Insulin Delivery Systems
7.3.1 Altea Therapeutics Transdermal Passport(TM) System
7.3.2 Technosphere�/Insulin Mimics Early Post-Prandial Insulin Release
7.4 Profiles of Key Novel Late-Stage Drugs
7.5 Major Marketed Drugs under Late-Stage Pipeline
7.5.1 Eisai's Actos
7.5.2 Amgen's Aranesp
7.5.3 Eli Lilly's Byetta
8 Global Metabolic Disorders Therapeutics Market: Competitive Landscape
8.1 Diabetes Market Overview
8.2 Market Share Analysis: Diabetes Therapeutics
8.3 Obesity Market Overview
8.4 Market Share Analysis: Obesity Therapeutics
8.5 Competitive Profiling
8.5.1 Novo Nordisk
8.5.2 Sanofi-aventis
8.5.3 Takeda
8.5.4 Eli Lilly
8.5.5 GlaxoSmithKline (GSK)
8.5.6 Merck & Co Inc.
8.5.7 Amylin Pharmaceuticals
8.5.8 Roche
8.5.9 Abbott
9 Global Metabolic Disorders Therapeutics Market: M&A Landscape
9.1 Overview
9.1.1 Ligand Pharmaceuticals acquired Metabasis Therapeutics in October 2009
9.1.2 CombinatoRx, Inc. Acquired Neuromed Pharmaceuticals, Inc. in August 2009
9.1.3 Mylan Laboratories Acquired Matrix Laboratories Limited in March 2009
9.1.4 Pfizer Acquired Wyeth in January 2009
9.1.5 Wyeth Acquired Thiakis Ltd. in December 2008
9.1.6 Bellus Health Inc. Acquired Innodia Inc in July 2008
9.1.7 GlaxoSmithKline Acquired Sirtris Pharmaceuticals in April 2008
9.1.8 Point Therapeutics and Dara Biosciences Merged in February 2008
9.1.9 Teva Pharmaceutical Industries Acquired Cogenesys, Inc. in January 2008
9.2 R&D Licensing Agreements
9.2.1 Deals by Indication
9.2.2 Deals by Phase
9.2.3 Deals by Geography
9.2.4 Deals by Licensing Type
9.2.5 Deals by Value ($)
9.2.6 Preclinical
9.2.7 Phase I
9.2.8 Phase II
9.2.9 Phase III
9.2.10 Approved
10 Appendix
10.1 Market Definitions
10.2 Key Support Data
10.3 Abbreviations
10.4 Research Methodology
10.4.1 Epidemiology-based Forecasting
10.5 Related Reports
10.6 Contact Us
10.7 Disclaimer
10.8 Sources
1.1 List of Tables
Table 1: Metabolic Disorders Market, Global, Sales Value ($ bn), 2000-2008
Table 2: Metabolic Disorders Market, Global, Sales Value ($ bn), 2008-2015
Table 3: Metabolic Disorders Market, Global, Sales Volume (bn), 2000-2008
Table 4: Metabolic Disorders Market, Global, Sales Volume (bn), 2008-2015
Table 5: Metabolic Disorders Market, Global, Annual Cost of Therapy ($), 2000-2008
Table 6: Metabolic Disorders Market, Global, Annual Cost of Therapy ($), 2008-2015
Table 7: Metabolic Disorders Market, Global, Treatment Usage Patterns, 2000-2008
Table 8: Metabolic Disorders Market, Global, Treatment Usage Patterns, 2008-2015
Table 9: Metabolic Disorders Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2000-2008
Table 10: Metabolic Disorders Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2008-2015
Table 11: Metabolic Disorders Market, US, Sales Value ($ bn), 2000-2008
Table 12: Metabolic Disorders Market, US, Sales Value ($ bn), 2008-2015
Table 13: Metabolic Disorders Market, US, Sales Volume (bn), 2000-2008
Table 14: Metabolic Disorders Market, US, Sales Volume (bn), 2008-2015
Table 15: Metabolic Disorders Market, US, Annual Cost of Therapy ($), 2000-2008
Table 16: Metabolic Disorders Market, US, Annual Cost of Therapy ($), 2008-2015
Table 17: Metabolic Disorders Market, US, Treatment Usage Patterns, 2000-2008
Table 18: Metabolic Disorders Market, US, Treatment Usage Patterns, 2008-2015
Table 19: Metabolic Disorders Market, Top Five Countries in Europe, Sales Value ($ bn), 2000-2008
Table 20: Metabolic Disorders Market, Top Five Countries in Europe, Sales Value ($ bn), 2008-2015
Table 21: Metabolic Disorders Market, Top Five Countries in Europe, Sales Volume (bn), 2000-2008
Table 22: Metabolic Disorders Market, Top Five Countries in Europe, Sales Volume (bn), 2008-2015
Table 23: Metabolic Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2000-2008
Table 24: Metabolic Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2008-2015
Table 25: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns, 2000-2008
Table 26: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns, 2008-2015
Table 27: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2000-2008
Table 28: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2008-2015
Table 29: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2000-2008
Table 30: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2008-2015
Table 31: Metabolic Disorders Market, Japan, Annual Cost of Therapy ($), 2000-2008
Table 32: Metabolic Disorders Market, Japan, Annual Cost of Therapy ($), 2008-2015
Table 33: Metabolic Disorders Market, Japan, Treatment Usage Patterns, 2000-2008
Table 34: Metabolic Disorders Market, Japan, Treatment Usage Patterns, 2008-2015
Table 35: Metabolic Disorders Market, Global, Diabetes Sales Value ($ bn), 2000-2008
Table 36: Metabolic Disorders Market, Global, Diabetes Sales Value ($ bn), 2008-2015
Table 37: Metabolic Disorders, Global, Diabetes Sales Volume (billion), 2000-2008
Table 38: Metabolic Disorders, Global, Diabetes Sales Volume (billion), 2008-2015
Table 39: Metabolic Disorders Market, Global, Diabetes Annual Cost of Therapy ($), 2000-2008
Table 40: Metabolic Disorders Market, Global, Diabetes Annual Cost of Therapy ($), 2008-2015
Table 41: Metabolic Disorders, Global, Diabetes Treatment Usage Patterns, 2000-2008
Table 42: Metabolic Disorders, Global, Diabetes Treatment Usage Patterns, 2008-2015
Table 43: Metabolic Disorders Market, Global, Diabetes Market Geographical Segmentation, 2000-2008
Table 44: Metabolic Disorders Market, Global, Diabetes Market Geographical Segmentation, 2008-2015
Table 45: Metabolic Disorders Market, Global, Diabetes Branded Vs Generics, 2000-2008
Table 46: Metabolic Disorders Market, Global, Diabetes Branded Vs Generics, 2008-2015
Table 47: Metabolic Disorders Market, Global, Obesity Diseases Population, 2000-2008
Table 48: Metabolic Disorders Market, Global, Obesity Diseases Population, 2008-2015
Table 49: Metabolic Disorders Market, Global, Obesity Market Sales Volume (billion), 2000-2008
Table 50: Metabolic Disorders Market, Global, Obesity Market Sales Volume (billion), 2008-2015
Table 51: Metabolic Disorders Market, Global, Annual Cost of Obesity Treatment, 2000-2008
Table 52: Metabolic Disorders Market, Global, Annual Cost of Obesity Treatment, 2008-2015
Table 53: Metabolic Disorders Market, Global, Obesity Treatment Usage Patterns, 2000-2008
Table 54: Metabolic Disorders Market, Global, Obesity Treatment Usage Patterns, 2008-2015
Table 55: Metabolic Disorders Market, Global, Obesity Market Geographical Segmentation, 2000-2008
Table 56: Metabolic Disorders Market, Global, Obesity Market Geographical Segmentation, 2008-2015
Table 57: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs, 2000-2008
Table 58: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs, 2008-2015
Table 59: Metabolic Disorders Therapeutics Market, Novo Nordisk, Pipeline Products, December 2009
Table 60: Metabolic Disorders Therapeutics Market, Sanofi-Aventis, Pipeline Products, December 2009
Table 61: Metabolic Disorders Therapeutics Market, Takeda, Pipeline Products, December 2009
Table 62: Metabolic Disorders Therapeutics Market, Eli Lilly, Pipeline Products, December 2009
Table 63: Metabolic Disorders Therapeutics Market, GSK, Pipeline Products, December 2009
Table 64: Metabolic Disorders Therapeutics Market, Merck, Pipeline Products, December 2009
Table 65: Metabolic Disorders Therapeutics Market, Amylin, Pipeline Products, December 2009
Table 66: Metabolic Disorders Therapeutics Market, Roche, Pipeline Products, December 2009
Table 67: Metabolic Disorders Therapeutics Market, Global, Major M&A Deals, 2008-2009
Table 68: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009
Table 69: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2009
Table 70: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2009
Table 71: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2009
Table 72: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008-2009
List of Figures
Figure 1: Metabolic Disorders Market, Global, Market Drivers and Restraints, 2008
Figure 2: Metabolic Disorders Market, Global, Sales Value ($ bn), 2000-2015
Figure 3: Metabolic Disorders Market, Global, Sales Volume (bn), 2000-2015
Figure 4: Metabolic Disorders Market, Global, Annual Cost of Therapy ($), 2000-2015
Figure 5: Metabolic Disorders Market, Global, Treatment Usage Patterns, 2000-2015
Figure 6: Metabolic Disorders Market, Global, Diseased Population (million), 2000-2015
Figure 7: Metabolic Disorders Market, Global, Treatment Seeking Population (million), 2000-2015
Figure 8: Metabolic Disorders Market, Global, Diagnosed Population (million), 2000-2015
Figure 9: Metabolic Disorders Market, Global, Prescription Population (million), 2000-2015
Figure 10: Metabolic Disorders Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2000-2015
Figure 11: Metabolic Disorders Market, Global, SWOT Analysis, 2008
Figure 12: Metabolic Disorders Market, Global, Drivers and Restraints, 2008
Figure 13: Metabolic Disorders Market, US, Sales Value ($ bn), 2000-2015
Figure 14: Metabolic Disorders Market, US, Sales Volume (bn), 2000-2015
Figure 15: Metabolic Disorders Market, US, Annual Cost of Therapy ($), 2000-2015
Figure 16: Metabolic Disorders Market, US, Treatment Usage Patterns, 2000-2015
Figure 17: Metabolic Disorders Market, US, Diseased Population, 2000-2015
Figure 18: Metabolic Disorders Market, US, Treatment Seeking Population, 2000-2015
Figure 19: Metabolic Disorders Market, US, Diagnosed Population, 2000-2015
Figure 20: Metabolic Disorders Market, US, Prescription Population, 2000-2015
Figure 21: Metabolic Disorders Market, Top Five Countries in Europe, Sales Value ($ bn), 2000-2015
Figure 22: Metabolic Disorders Market, Top Five Countries in Europe, Sales Volume (bn), 2000-2015
Figure 23: Metabolic Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2000-2015
Figure 24: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns, 2000-2015
Figure 25: Metabolic Disorders Market, Top Five Countries in Europe, Diseased Population, 2000-2015
Figure 26: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Seeking Population, 2000-2015
Figure 27: Metabolic Disorders Market, Top Five Countries in Europe, Diagnosed Population, 2000-2015
Figure 28: Metabolic Disorders Market, Top Five Countries in Europe, Prescription Population, 2000-2015
Figure 29: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2000-2015
Figure 30: Metabolic Disorders Market, Japan, Sales Volume ($ bn), 2000-2015
Figure 31: Metabolic Disorders Market, Japan, Annual Cost of Therapy ($), 2000-2015
Figure 32: Metabolic Disorders Market, Japan, Treatment Usage Patterns, 2000-2015
Figure 33: Metabolic Disorders Market, Japan, Diseased Population, 2000-2015
Figure 34: Metabolic Disorders Market, Japan, Treatment Seeking Population, 2000-2015
Figure 35: Metabolic Disorders Market, Japan, Diagnosed Population, 2000-2015
Figure 36: Metabolic Disorders Market, Japan, Prescription Population, 2000-2015
Figure 37: Metabolic Disorders Market, Global, Diabetes Sales Value ($ bn), 2000-2015
Figure 38: Metabolic Disorders, Global, Diabetes Sales Volume (billion), 2000-2015
Figure 39: Metabolic Disorders Market, Global, Diabetes Annual Cost of Therapy ($), 2000-2015
Figure 40: Metabolic Disorders, Global, Diabetes Treatment Usage Patterns, 2000-2015
Figure 41: Metabolic Disorders Market, Global, Diabetes Diseased Population, 2000-2015
Figure 42: Metabolic Disorders Market, Global, Diabetes Treatment Seeking Population, 2000-2015
Figure 43: Metabolic Disorders Market, Global, Diabetes Diagnosed Population, 2000-2015
Figure 44: Metabolic Disorders Market, Global, Diabetes Prescription Population, 2000-2015
Figure 45: Metabolic Disorders Market, Global, Diabetes Market Segmentation by Geography, 2008 and 2015
Figure 46: Metabolic Disorders Market, Global, Diabetes Market Geographical Segmentation, 2000-2015
Figure 47: Metabolic Disorders Market, Global, Diabetes Market, Geography Benchmarking, 2008
Figure 48: Metabolic Disorders Market, Global, Diabetes Branded Vs Generics, 2000-2015
Figure 49: Metabolic Disorders Market, Global, Diabetes Market, Generics Share, 2008 and 2015
Figure 50: Metabolic Disorders Market, Global, Diabetes Market Drivers and Restraints, 2008
Figure 51: Metabolic Disorders Market, Global, Obesity Diseases Population, 2000-2015
Figure 52: Metabolic Disorders Market, Global, Obesity Market Sales Volume (billion), 2000-2015
Figure 53: Metabolic Disorders Market, Global, Annual Cost of Obesity Treatment, 2000-2015
Figure 54: Metabolic Disorders Market, Global, Obesity Treatment Usage Patterns, 2000-2015
Figure 55: Metabolic Disorders Market, Global, Obesity Diseased Population, 2000-2015
Figure 56: Metabolic Disorders Market, Global, Obesity Treatment Seeking Population, 2000-2015
Figure 57: Metabolic Disorders Market, Global, Obesity Diagnosed Population, 2000-2015
Figure 58: Metabolic Disorders Market, Global, Obesity Prescription Population, 2000-2015
Figure 59: Metabolic Disorders Market, Global, Obesity Market Geographical Segmentation, 2000-2015
Figure 60: Metabolic Disorders Market, Global, Obesity Market Distribution by Geography, 2008 and 2015
Figure 61: Metabolic Disorders Market, Global, Obesity Market, Geography Benchmarking, 2008 and 2015
Figure 62: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs, 2000-2015
Figure 63: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs Market Share, 2008 and 2015
Figure 64: Metabolic Disorders Market, Global, Obesity Market Drivers and Restraints, 2009
Figure 65: Diabetes Therapeutics Market, Global, Revenue of Top Six Players, 2006-2008
Figure 66: Metabolic Disorder Market, Global, Competitive Analysis of Top Three Manufacturers in the Diabetes Market, 2006-2008
Figure 67: Diabetes Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
Figure 68: Obesity Therapeutics Market, Global, Revenue of Top Six Players, 2006-2008
Figure 69: Metabolic Disorder Market, Global, Competitive Analysis of Top Three Manufacturers in the Obesity Market, 2006-2008
Figure 70: Obesity Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
Figure 71: Diabetes Therapeutics Market, Global, Competitive Landscape, 2008
Figure 72: Metabolic Disorders Therapeutics Market, Global, Novo Nordisk, Revenue Segmentation, 2008
Figure 73: Metabolic Disorders Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product, 2008
Figure 74: Metabolic Disorders Therapeutics Market, Sanofi-Aventis, Revenue Segmentation, 2008
Figure 75: Metabolic Disorders Therapeutics Market, Sanofi-aventis, Diabetes Revenue by Product, 2008
Figure 76: Metabolic Disorders Therapeutics Market, Takeda, Diabetes Revenue as Percentage of Total Revenue, 2008
Figure 77: Metabolic Disorders Therapeutics Market, Eli Lilly, Diabetes Revenue as Percentage of Total Revenue, 2008
Figure 78: Metabolic Disorders Therapeutics Market, Eli Lilly, Diabetes Revenue by Product, 2008
Figure 79: Metabolic Disorders Therapeutics Market, GlaxoSmithKline, Revenue Segmentation, 2008
Figure 80: Metabolic Disorders Therapeutics Market, GSK, Diabetes Revenue by Product, 2008
Figure 81: Metabolic Disorders Therapeutics Market, Merck, Revenue Segmentation, 2008
Figure 82: Metabolic Disorders Therapeutics Market, Amylin, Revenue Segmentation, 2008
Figure 83: Metabolic Disorders Therapeutics Market, GSK, Diabetes Revenue by Product, 2008
Figure 84: Metabolic Disorders Therapeutics Market, Roche, Revenue Segmentation, 2008
Figure 85: Metabolic Disorders Therapeutics Market, Abbott, Revenue Segmentation, 2008
Figure 86: Metabolic Disorders Therapeutics Market, Global, M&A Deals by Indication, 2008-2009
Figure 87: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Indication, 2008-2009
Figure 88: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-2009
Figure 89: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Geography, 2008-2009
Figure 90: Metabolic Disorders Therapeutics Market, Global, Major Agreements By Type, 2008-2009
Figure 91: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Value, 2008-2009
Figure 92: GBI Research Market Forecasting Model
Companies mentioned
Novo Nordisk
Sanofi-aventis
Takeda
Eli Lilly
GlaxoSmithKline (GSK)
Merck & Co Inc.
Amylin Pharmaceuticals
Roche
Abbott Laboratories
To order this report:
Pharmaceutical Industry: The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
More Market Research Report
Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
